Report Contents
Market Overview
The global Endoluminal Suturing Devices market is currently valued at approximately USD 0.42 Billion in 2025 and is projected to reach about USD 0.47 Billion in 2026, before expanding to roughly USD 0.89 Billion by 2032. This trajectory reflects a sustained compound annual growth rate of 11.20% from 2026 to 2032, driven by the rapid adoption of minimally invasive endoscopic interventions in bariatric, gastrointestinal, and interventional oncology procedures.
As endoluminal suturing systems move from niche use cases into routine therapeutic endoscopy, success in this market increasingly depends on scalability of platform architectures, localization of product portfolios to meet regulatory and anatomical practice variations, and deep technological integration with imaging, robotics, and digital workflow solutions. Converging trends, including outpatient procedure migration, value-based healthcare models, and advances in endoscopic visualization, are expanding the market’s scope and redefining its future direction toward fully integrated endoluminal therapy ecosystems. This report is positioned as an essential strategic tool, providing forward-looking analysis to guide capital allocation, partnership strategies, and innovation roadmaps amid accelerating opportunities and disruptive competitive dynamics in endoluminal suturing devices.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Endoluminal Suturing Devices Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Endoluminal Suturing Devices Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Endoscopic suturing systems:
Endoscopic suturing systems currently represent the most advanced and clinically versatile segment of the endoluminal suturing devices market, anchoring a substantial portion of global revenue. These platforms integrate motorized or mechanically assisted needle drivers, anchor deployment, and precision controls to enable full-thickness tissue approximation during flexible endoscopy. In bariatric endoscopy and gastrointestinal defect closure, leading systems have demonstrated technical success rates frequently exceeding 90.00%, which has reinforced their position as the go-to solution in high-complexity procedures.
The main competitive advantage of endoscopic suturing systems lies in their ability to replicate laparoscopic suturing functionality via a flexible endoscope, thereby reducing the need for invasive surgery and shortening average hospital stays by an estimated 20.00% to 40.00%. This capability translates into lower total cost of care, rapid patient turnover, and higher utilization rates in endoscopy suites, giving providers a concrete economic incentive to adopt these platforms. Growth is being catalyzed by the global expansion of endoscopic bariatric therapies, such as endoscopic sleeve gastroplasty and revisional bariatric procedures, where demand for durable full-thickness sutures and reproducible tissue plications is accelerating year over year.
-
Over-the-scope suturing and clipping devices:
Over-the-scope suturing and clipping devices occupy a critical niche in the market by providing robust mechanical closure for acute gastrointestinal defects, including perforations, anastomotic leaks, and high-risk bleeding lesions. These cap-mounted devices are deployed over the tip of an endoscope and can grasp, approximate, and lock tissue in a single or few maneuvers, making them particularly valuable in emergency and interventional endoscopy settings. Their market position is strong in tertiary care centers and advanced endoscopy units where rapid, reliable defect closure is essential to avoid surgical conversion.
The competitive edge of over-the-scope systems stems from their high immediate closure success and hemostasis rates, which in many clinical series surpass 85.00% to 90.00% for selected indications, along with a relatively short learning curve compared with full suturing platforms. By enabling definitive endoscopic management of leaks and perforations, they can reduce the need for surgical rescue procedures and associated intensive care stays, resulting in meaningful cost avoidance per case. Current growth is driven by the rising incidence of complex endoscopic interventions, such as endoscopic submucosal dissection and full-thickness resection, which create larger wall defects and therefore increase demand for high-strength over-the-scope closure solutions.
-
Standalone suturing instruments and accessories:
Standalone suturing instruments and accessories include needle holders, tissue graspers, suture cutters, and dedicated endoscopic suturing aids that can be paired with standard flexible endoscopes. This segment plays a supporting yet strategically important role, especially in facilities that want to enhance their suturing capabilities without initially investing in full integrated platforms. Many endoscopy units in emerging markets rely on such modular solutions to extend the therapeutic reach of their existing equipment base.
The key competitive advantage of these standalone tools is their lower capital cost and high configurability, which can reduce upfront equipment expenditure by an estimated 30.00% to 50.00% compared with premium integrated suturing systems. While they may require more manual dexterity and longer procedure times, they allow clinicians to perform targeted tissue approximation, anchoring, or reinforcement in selected cases at a more accessible price point. Growth in this category is primarily propelled by hospital cost-containment strategies and the expansion of GI therapeutic services in mid-tier hospitals and ambulatory endoscopy centers, where budget constraints favor incremental upgrades over comprehensive platform purchases.
-
Single-use suturing kits:
Single-use suturing kits comprise pre-packaged, sterile sets of suturing components tailored for specific endoluminal indications, such as mucosal defect closure after endoscopic mucosal resection, bariatric revisions, or stent fixation. These kits deliver a standardized configuration of instruments, sutures, and accessories intended for one procedure, which simplifies logistic planning and minimizes the risk of missing components during time-sensitive cases. As infection control standards become increasingly stringent, these disposable kits are gaining traction, particularly in outpatient and high-throughput endoscopy environments.
The primary competitive advantage of single-use kits is the reduction of reprocessing labor, device turnaround times, and cross-contamination risk, often lowering central sterile department workload associated with suturing devices by an estimated 25.00% to 35.00%. Although per-case device costs can be higher than reusable alternatives, many facilities recoup this expense through improved scheduling predictability and higher daily procedure volumes. The main growth catalyst for this segment is the global shift toward ambulatory endoscopic interventions and value-based care models, where predictable per-procedure costs, streamlined workflow, and strong infection prevention performance are prioritized.
-
Endoscopic suturing reloads and consumables:
Endoscopic suturing reloads and consumables form the recurring revenue backbone of the endoluminal suturing devices market, encompassing suture cartridges, anchors, needles, clips, and single-use components specific to each platform. Once a healthcare provider installs an endoscopic suturing system, ongoing demand for these consumables generates a multi-year utilization stream that significantly influences the overall market value. In many mature installations, consumables can account for a substantial portion of lifecycle spending, making this segment strategically important for both manufacturers and investors.
The competitive strength of reloads and consumables lies in their procedural indispensability and platform-specific design, which drives high attachment rates and reduces the likelihood of switching to competing systems. In busy bariatric and interventional endoscopy centers, case volumes can translate into dozens or even hundreds of consumable reloads per month per platform, creating a predictable revenue pattern with attractive margins. The principal growth catalyst for this segment is the expanding installed base of advanced suturing systems worldwide, combined with rising procedure volumes for obesity management, GERD interventions, and complex GI defect closures, which collectively push up per-site consumable throughput year after year.
Market By Region
The global Endoluminal Suturing Devices market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a strategic anchor for the Endoluminal Suturing Devices market, combining advanced bariatric surgery programs with high adoption of minimally invasive endoscopic interventions. The region benefits from strong reimbursement frameworks, a dense network of accredited bariatric centers, and rapid integration of suturing platforms into therapeutic endoscopy suites. The United States and Canada jointly drive innovation through academic medical centers that run early clinical trials and generate procedural guideline influence worldwide.
North America is estimated to command a significant portion of global revenue, providing a mature yet still expanding demand base that stabilizes overall market growth. Untapped potential lies in expanding usage beyond tertiary hospitals into ambulatory surgery centers and community hospitals, especially for endoscopic revision of failed bariatric procedures. Key challenges include capital budget constraints in smaller facilities and the need for extensive physician training to standardize complex suturing techniques.
-
Europe:
Europe holds strategic importance as a diversified Endoluminal Suturing Devices market, characterized by strong clinical governance, multicenter trials, and strict device assessment processes. Leading markets such as Germany, the United Kingdom, France, and Italy act as primary adopters, with robust endoscopy ecosystems and sizable obese and gastroesophageal reflux disease populations. These hubs drive procedural standardization and influence adoption across Central and Eastern Europe through training networks.
Europe accounts for a substantial share of global procedures, contributing a stable and moderately growing revenue stream that supports long-term industry planning. Significant opportunities remain in Southern and Eastern European countries where bariatric penetration and therapeutic endoscopy volumes are still relatively low. However, heterogeneous reimbursement policies, cost-containment pressures in public hospitals, and varying recognition of endoluminal bariatric procedures pose barriers that manufacturers must navigate with tailored health economic evidence.
-
Asia-Pacific:
The Asia-Pacific region is emerging as a high-growth corridor for Endoluminal Suturing Devices, underpinned by rising obesity rates, expanding private hospital chains, and increasing investments in advanced endoscopy infrastructure. Markets such as Australia, India, Southeast Asia, and certain Gulf-influenced hubs in the wider region are accelerating adoption as clinicians seek less invasive alternatives to surgical bariatric procedures. Medical tourism, particularly for weight-loss and metabolic interventions, further elevates the strategic relevance of this region.
Asia-Pacific is estimated to hold a growing but still underpenetrated share of the global market, contributing disproportionately to future volume expansion rather than current revenue dominance. Untapped potential is notable in large urban clusters and secondary cities where endoscopy capacity is increasing but complex suturing solutions remain unavailable. Key challenges include affordability constraints, uneven training access for endoscopists, and limited reimbursement in emerging economies, necessitating tiered pricing, robust training programs, and partnerships with private hospital networks.
-
Japan:
Japan is a specialized and technologically advanced Endoluminal Suturing Devices market, with high procedure quality standards and an established culture of therapeutic endoscopy. University hospitals and large urban medical centers lead adoption, leveraging sophisticated endoscopic platforms and a strong domestic medical device ecosystem. Japan’s rigorous regulatory and clinical evaluation environment also makes it a reference market for demonstrating safety and efficacy in complex gastric and esophageal procedures.
Japan accounts for a meaningful share of regional Asia-Pacific revenues and provides a stable, innovation-focused segment with moderate but steady growth. Significant untapped potential exists in expanding indications beyond bariatric applications, such as defect closure, post-ESD management, and prevention of procedural complications. Barriers include strict reimbursement approval processes, conservative adoption in smaller community hospitals, and a need for extensive hands-on training to integrate suturing systems into routinely performed therapeutic interventions.
-
Korea:
Korea represents a dynamic, innovation-friendly market for Endoluminal Suturing Devices, supported by high healthcare digitization, strong endoscopy volumes, and rapid acceptance of minimally invasive technologies. Leading tertiary hospitals in Seoul and other major cities act as early adopters, often participating in multinational clinical studies and showcasing advanced endoscopic bariatric techniques. The country’s emphasis on medical branding and international patient attraction further enhances its strategic significance.
Korea currently contributes a modest but fast-growing share of global demand, functioning as a regional showcase within Northeast Asia for complex endoluminal therapies. Untapped opportunities include broader rollout to secondary hospitals and private gastroenterology clinics, where interest is rising but capital investment remains cautious. Challenges center on reimbursement negotiations, cost-effectiveness scrutiny, and the need to cultivate a larger pool of endoscopists proficient in suturing device operation through structured proctorship and simulation-based training.
-
China:
China is rapidly evolving into one of the most consequential growth engines for the Endoluminal Suturing Devices market, driven by a large obese and pre-diabetic population, rising disposable incomes, and extensive hospital infrastructure expansion. Major metropolitan areas such as Beijing, Shanghai, Guangzhou, and Shenzhen host high-volume tertiary hospitals that are investing in advanced therapeutic endoscopy and exploring endoscopic sleeve gastroplasty and revision techniques. Domestic manufacturing capabilities are also beginning to emerge, increasing competitive intensity.
China currently holds a growing share of global revenues but remains significantly underpenetrated relative to its procedure potential, making it a critical long-term growth frontier. Untapped potential is substantial in Tier 2 and Tier 3 cities, where bariatric surgery access is limited and endoscopic alternatives could offer scalable solutions. Key hurdles include uneven reimbursement coverage, price sensitivity in public hospitals, complex regulatory pathways for imported systems, and the need to develop comprehensive training ecosystems to standardize procedural outcomes across a vast provider base.
-
USA:
The USA is the single most influential national market for Endoluminal Suturing Devices, combining high obesity prevalence with a mature network of bariatric and advanced endoscopy centers. Large integrated health systems, academic hospitals, and specialized weight-loss clinics drive early adoption of endoscopic sleeve gastroplasty, revision of gastric bypass, and complex defect closure procedures. Strong venture funding and clinical research output from American institutions further shape global best practices and device feature roadmaps.
The USA accounts for a dominant share of North American revenue and a significant portion of global market size, providing both a mature revenue core and continued high-growth pockets in outpatient and ambulatory settings. Untapped potential resides in expanding procedural adoption into community hospitals and freestanding endoscopy centers, as well as integrating suturing devices into broader metabolic disease management programs. Challenges include reimbursement variability across payers, stringent cost-benefit assessments, and the need for scalable training programs that reduce learning curves and improve productivity for gastroenterologists and bariatric endoscopists.
Market By Company
The Endoluminal Suturing Devices market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Apollo Endosurgery Inc.:
Apollo Endosurgery Inc. occupies a central position in the endoluminal suturing devices market due to its early and focused specialization in endoscopic bariatric and gastrointestinal closure solutions. The company’s OverStitch platforms have become reference technologies for endoscopic sleeve gastroplasty, revision of bariatric surgery, and full-thickness defect closure, which directly drives procedural adoption across advanced endoscopy centers and obesity treatment programs. This specialization ensures that the company remains closely aligned with key growth segments such as minimally invasive obesity management and complex GI defect repair.
In 2025, Apollo Endosurgery is estimated to generate endoluminal suturing device revenue of USD 0.07 Billion, corresponding to a market share of approximately 16.70% within the global endoluminal suturing devices segment. These figures indicate that Apollo is one of the category leaders by revenue despite facing competition from diversified medical device corporations with larger overall portfolios. Its share reflects strong brand recognition among interventional gastroenterologists and bariatric endoscopists, as well as favorable clinical data supporting durable outcomes in endoscopic weight loss procedures.
Apollo’s competitive differentiation stems from its deep procedural focus, robust training infrastructure, and strong relationships with centers of excellence in metabolic and bariatric endoscopy. The company invests heavily in physician education, proctoring, and clinical evidence generation, which lowers adoption barriers for complex endoscopic suturing. While larger conglomerates compete on breadth of endoscopy platforms, Apollo’s narrow but deep emphasis on endoluminal suturing allows it to innovate quickly, refine device ergonomics, and bundle its solutions with procedure-specific protocols that support hospital value analysis committees and payers.
-
Ethicon Inc.:
Ethicon Inc., a subsidiary focused on surgical technologies, plays a significant role in the endoluminal suturing devices market through its extensive heritage in suturing, stapling, and tissue closure. The company leverages decades of experience in surgical sutures and minimally invasive surgery to design endoluminal solutions that integrate well with broader operating room workflows and perioperative protocols. Its strong trust among surgeons and hospital procurement teams enables faster inclusion of its endoluminal devices into capital and disposable purchasing cycles.
By 2025, Ethicon’s participation in the endoluminal suturing space is estimated to generate revenue of USD 0.06 Billion, translating into a market share of around 15.00%. These values demonstrate that Ethicon is a top-tier player whose scale and installed base in laparoscopy and flexible endoscopy give it an advantage in cross-selling suturing platforms. Its market position reflects the leveraging of existing distribution networks, strong brand equity in suture technology, and integration of endoluminal tools into multi-procedure contracts with hospital systems.
Ethicon’s key strategic advantages include its broad portfolio of closure solutions, strong evidence base in tissue healing, and the ability to bundle endoluminal suturing devices with energy systems, staplers, and surgical sutures in value-based procurement arrangements. The company can deploy its clinical education infrastructure, including simulation labs and digital learning platforms, to train surgeons and gastroenterologists in hybrid and purely endoluminal procedures. This combination of scale, cross-portfolio bundling, and clinical support positions Ethicon as a formidable competitor for hospitals seeking standardized closure solutions across multiple procedural settings.
-
Olympus Corporation:
Olympus Corporation is a cornerstone player in the gastrointestinal endoscopy ecosystem, and its role in the endoluminal suturing devices market is closely tied to its dominance in endoscope platforms, imaging, and therapeutic accessories. The company’s endoluminal suturing offerings benefit from seamless compatibility with its widely installed endoscopy systems, which simplifies adoption and reduces integration challenges for hospitals and ambulatory surgery centers. This tight integration allows Olympus to position suturing solutions as part of a complete advanced endoscopy toolkit.
In 2025, Olympus is expected to deliver endoluminal suturing device revenue of approximately USD 0.05 Billion, corresponding to a market share of about 11.90%. These figures underline the company’s strong presence despite endoluminal suturing representing only a small fraction of its overall endoscopy business. The market share is supported by Olympus’s global footprint, extensive key account relationships, and the ability to integrate suturing into existing procurement frameworks for imaging systems and endoscopic accessories.
Olympus differentiates itself through technology integration, image-guided precision, and a comprehensive portfolio that supports complex GI interventions such as endoscopic submucosal dissection, full-thickness resection, and bariatric endotherapy. Its strategic advantage lies in providing physicians with a complete therapeutic ecosystem: advanced scopes, high-definition visualization, energy devices, and suturing tools that are designed to work together. This ecosystem approach allows Olympus to promote procedural standardization, improve workflow efficiency, and support clinical training programs in collaboration with leading academic centers.
-
Boston Scientific Corporation:
Boston Scientific Corporation holds a strong strategic position in interventional gastroenterology and endoscopy, and it extends this presence into the endoluminal suturing devices market. The company’s portfolio in stents, hemostasis devices, and tissue resection technologies positions it naturally to integrate suturing solutions for defect closure and lumen remodeling. Its focus on complex GI interventions and oncology-related procedures ensures that endoluminal suturing is embedded within high-value clinical pathways.
For 2025, Boston Scientific’s revenue from endoluminal suturing devices is estimated at USD 0.04 Billion, representing a market share of roughly 9.50%. This level of participation reflects a strong yet still expanding footprint, as the company continues to deepen its advanced endoscopy portfolio. The revenue and share suggest that Boston Scientific is a key competitor with room to capture additional volume through portfolio synergies and targeted innovation.
Boston Scientific’s competitive advantage lies in its deep interventional expertise, robust clinical evidence in GI therapeutics, and strong relationships with interventional endoscopists and tertiary care centers. The company can bundle endoluminal suturing solutions with other advanced tools such as lumen-apposing metal stents, ESD accessories, and hemostasis products to create procedural packages optimized for complex defect closure and fistula management. This integrated approach, combined with a focus on outcomes-driven value propositions, enables Boston Scientific to position its suturing solutions as enablers of shorter hospital stays and reduced complication rates.
-
Medtronic plc:
Medtronic plc is a global leader in medical technology, and its role in the endoluminal suturing devices market is enhanced by its broad portfolio spanning gastrointestinal, bariatric, and minimally invasive surgery. While endoluminal suturing represents a niche within Medtronic’s overall business, the company leverages its strength in surgical stapling, energy, and navigation to support the development and commercialization of advanced endoscopic closure tools. Its scale enables substantial investment in R&D and clinical studies that inform adoption across multiple geographies.
In 2025, Medtronic’s endoluminal suturing device revenue is projected to be around USD 0.03 Billion, equating to a market share near 7.10%. These figures demonstrate that the company is an important but not yet dominant player in this specific niche, with considerable upside if it chooses to intensify its focus. The current share reflects a strategy where endoluminal suturing complements, rather than anchors, its gastrointestinal solutions portfolio.
Medtronic’s key strategic strengths include its global distribution network, strong regulatory capabilities, and the ability to integrate endoluminal suturing technologies into broader metabolic and bariatric treatment pathways. The company can connect suturing solutions with continuous patient monitoring and digital health tools, creating a differentiated value proposition for integrated care. Its capabilities in data analytics, remote support, and training can be leveraged to drive broader adoption in emerging markets where complex endoscopy infrastructure is still developing.
-
Erbe Elektromedizin GmbH:
Erbe Elektromedizin GmbH is best known for its electrosurgical and thermal therapy systems, but it also plays a supportive role in the endoluminal suturing devices market by enabling advanced endoscopic interventions that frequently require secure closure. While suturing is not its core portfolio, Erbe’s technologies are often used in combination with endoluminal suturing during complex mucosal resections and full-thickness excisions. This adjacency positions Erbe as an important ecosystem partner in advanced therapeutic endoscopy.
For 2025, Erbe’s revenue directly attributable to endoluminal suturing devices is estimated at EUR 0.01 Billion, delivering a market share of approximately 2.40%. These figures highlight a relatively small but meaningful presence, especially in high-end European endoscopy centers where integrated use of energy and closure devices is routine. The share reflects a focus on select markets where Erbe’s installed base of energy platforms provides a natural channel for complementary suturing tools.
Erbe’s competitive advantages include its deep expertise in tissue effect modulation, long-standing relationships with advanced endoscopy units, and strong reputation for reliability in electrosurgical systems. When Erbe participates in endoluminal suturing, it can differentiate by emphasizing coordinated energy and closure strategies that minimize perforation risk and optimize hemostasis. This integrated clinical messaging resonates with interventional endoscopists who prioritize procedural safety and precision in complex GI interventions.
-
Ovesco Endoscopy AG:
Ovesco Endoscopy AG is a highly specialized company in the field of endoluminal tissue apposition and defect closure, best recognized for its over-the-scope clip systems. Its move into suturing and advanced closure solutions builds on deep biomechanical understanding of GI wall closure and robust clinical adoption in perforation management and fistula therapy. This expertise allows Ovesco to play an outsized role in the endoluminal suturing devices market relative to its overall corporate size.
In 2025, Ovesco’s endoluminal suturing-related revenue is estimated at EUR 0.02 Billion, representing a market share of around 4.80%. These values indicate a focused but influential player whose technologies are heavily used in high-acuity cases such as iatrogenic perforations and complex leaks. The market share reflects strong penetration in European advanced endoscopy centers and growing presence in North America and Asia-Pacific.
Ovesco’s strategic differentiation arises from its innovation focus on full-thickness closure, robust mechanical design, and close collaboration with thought leaders in interventional gastroenterology. The company emphasizes clinically demanding use cases where reliable closure is critical and where more generic solutions may be insufficient. This focus, combined with targeted training programs and strong clinical data in real-world perforation management, positions Ovesco as a go-to supplier for centers that manage high volumes of complex GI complications.
-
Cook Medical LLC:
Cook Medical LLC is a longstanding player in gastrointestinal endoscopy, with a broad portfolio that includes stents, biopsy devices, hemostasis tools, and enteral access solutions. Within the endoluminal suturing devices market, Cook leverages its deep relationships with GI endoscopy units and its reputation for reliable single-use devices. Its suturing and closure offerings complement its therapeutic portfolio in areas such as mucosal resection and fistula management.
For 2025, Cook Medical’s revenue from endoluminal suturing devices is projected at USD 0.02 Billion, corresponding to a market share of approximately 4.80%. These figures signal a meaningful yet mid-tier position, supported by targeted adoption in centers that already rely on Cook’s GI product range. The company’s share highlights the benefits of portfolio adjacency and cross-selling rather than a standalone focus on suturing.
Cook’s strategic advantages include its flexibility as a privately held company, its responsiveness to clinician feedback, and its ability to design niche devices tailored to specific procedural challenges. In endoluminal suturing, this translates into designs that prioritize ease of use, compatibility with a wide range of endoscopes, and cost-effective disposables that appeal to value-conscious hospitals. Cook can further differentiate by offering customized procedural kits that integrate suturing with hemostasis and resection accessories for specific GI indications.
-
PENTAX Medical:
PENTAX Medical is a major supplier of endoscopy systems and imaging solutions, and it participates in the endoluminal suturing devices market through accessory lines designed for compatibility with its GI platforms. While suturing is not the central pillar of its business, PENTAX sees endoluminal closure as an important enabler of advanced therapeutic procedures that drive utilization of its imaging and endoscope hardware. This ecosystem-driven approach aligns suturing adoption with the expansion of its installed base.
In 2025, PENTAX Medical’s estimated revenue from endoluminal suturing devices is USD 0.01 Billion, providing a market share of about 2.40%. These values highlight a modest but strategically relevant presence, primarily in regions where PENTAX endoscopes hold significant market share. The figures reflect a strategy that treats suturing as a complementary accessory category rather than a standalone growth driver.
PENTAX’s competitive differentiation lies in the seamless integration of accessories with imaging systems, ergonomic endoscope design, and its focus on image quality that supports precise endoluminal interventions. By ensuring that suturing tools are optimized for its scopes, PENTAX can offer reliable performance and simplified workflows to clinicians. Additionally, the company’s emphasis on infection control and reprocessing-compatible designs can enhance its value proposition for facilities seeking standardized and safe endoscopy operations.
-
STERIS plc:
STERIS plc is primarily known for sterilization, infection prevention, and surgical infrastructure solutions, but it also participates in the gastrointestinal endoscopy ecosystem through reprocessing, accessories, and select procedural tools. In the endoluminal suturing devices market, STERIS’s presence is emerging and typically tied to broader partnerships and portfolio expansions that support GI suites looking for integrated solutions from instrumentation to decontamination.
For 2025, STERIS’s revenue attributable to endoluminal suturing devices is estimated at USD 0.01 Billion, corresponding to a market share of roughly 2.40%. These figures describe an early-stage but strategically aligned position, with potential for expansion as STERIS strengthens its therapeutic product offerings in endoscopy. The current market share reflects a foothold rather than a dominant presence.
STERIS’s strategic advantage lies in its ability to bundle procedural tools, including endoluminal suturing devices, with comprehensive infection prevention, reprocessing equipment, and service contracts. This integrated approach appeals to hospitals seeking single-vendor solutions for endoscopy infrastructure and consumables. By aligning suturing adoption with compliance, safety, and workflow efficiency initiatives, STERIS can differentiate against competitors that focus solely on device performance without broader operational value propositions.
-
EndoGastric Solutions Inc.:
EndoGastric Solutions Inc. has a focused role in the endoluminal suturing devices market through its emphasis on transoral gastroesophageal reflux disease (GERD) therapies. Its devices are designed to reconstruct the gastroesophageal valve endoluminally, effectively requiring precision tissue apposition and durable suturing. This procedural specialization positions the company as a critical innovator in functional lumen-altering therapies rather than generic tissue closure.
In 2025, EndoGastric Solutions is expected to achieve endoluminal suturing-related revenue of USD 0.03 Billion, delivering a market share of approximately 7.10%. These figures illustrate that, despite its narrower indication focus, the company commands a significant portion of the market by volume in GERD-related endoluminal interventions. The share underscores the commercial success of its procedure-specific solutions and associated physician training programs.
EndoGastric Solutions differentiates itself through disease-focused product design, strong clinical data in GERD symptom improvement, and close collaboration with both gastroenterologists and foregut surgeons. The company’s suturing technologies are embedded in a complete therapeutic concept that includes patient selection criteria, standardized procedural steps, and long-term follow-up protocols. This integrated model allows it to engage payers, health systems, and providers with evidence-based economic arguments around reduced chronic medication use and improved quality of life.
-
Medigus Ltd.:
Medigus Ltd. is an innovation-driven company operating at the intersection of endoscopy and minimally invasive surgery, with particular emphasis on endoluminal approaches to esophageal disorders. In the endoluminal suturing devices market, Medigus contributes technology that enables transoral interventions aimed at conditions such as GERD, leveraging miniaturized visualization and suturing mechanisms. Its solutions emphasize reduced patient recovery times and avoidance of external incisions.
By 2025, Medigus’s revenue from endoluminal suturing-related products is estimated at USD 0.01 Billion, which corresponds to a market share of around 2.40%. These figures indicate a niche player with focused applications but meaningful visibility in specialized centers. The market share reflects early-stage commercialization with potential to scale as clinical evidence and reimbursement frameworks mature.
Medigus’s strategic advantages include its engineering expertise in ultra-miniaturized endoscopic systems, its agile development model, and its focus on procedures that can shift treatment from the operating room to outpatient or day-surgery environments. This positioning aligns well with health system priorities to reduce inpatient stays and overall costs of care. By continuing to build partnerships with larger device companies and academic centers, Medigus can leverage its technology platform to expand its role in endoluminal suturing and related interventions.
-
Endo Tools Therapeutics:
Endo Tools Therapeutics is an emerging innovator in advanced endoscopic instrumentation, with a focus on flexible devices that extend the therapeutic capabilities of standard endoscopes. Within the endoluminal suturing devices market, the company develops multi-functional tools that facilitate complex tissue manipulation, plication, and closure, enabling procedures traditionally requiring surgery to be performed endoscopically. Its devices are particularly relevant for bariatric endoscopy and structural GI interventions.
In 2025, Endo Tools Therapeutics is projected to generate endoluminal suturing-related revenue of EUR 0.01 Billion, yielding a market share of approximately 2.40%. These values highlight a growing but still early-stage commercial presence, driven mainly by adoption in specialized centers with a strong focus on innovation in therapeutic endoscopy. The market share reflects the impact of a focused product line with high clinical sophistication.
The company’s competitive differentiation lies in its engineering of add-on instruments that can be used with existing endoscope fleets, reducing the need for high capital expenditure by hospitals. This compatibility lowers barriers to adoption and enables physicians to perform advanced suturing and tissue apposition without replacing core imaging infrastructure. Endo Tools Therapeutics also benefits from close collaboration with European academic institutions, which accelerates clinical validation and real-world feedback for iterative product improvement.
-
GI Windows Medical:
GI Windows Medical focuses on novel, incisionless gastrointestinal interventions that rely on endoluminal tissue apposition and secure closure, particularly for metabolic and bariatric indications. Its technologies are designed to create controlled, durable communications or structural changes within the GI tract using endoscopic approaches that minimize trauma. This innovation places the company squarely within the endoluminal suturing devices market, even though its systems often integrate suturing with other tissue approximation mechanisms.
For 2025, GI Windows Medical’s endoluminal suturing-related revenue is estimated at USD 0.01 Billion, which translates into a market share of about 2.40%. These values reflect a high-innovation, early-commercialization company still scaling its footprint but already influencing the direction of metabolic endoscopy. The share underscores the market’s openness to disruptive procedural concepts that combine suturing with novel device architectures.
GI Windows Medical’s strategic strengths include its focus on clinically unmet needs in metabolic disease, its pursuit of incisionless alternatives to bariatric surgery, and its emphasis on demonstrating long-term outcomes. By orienting its product and clinical strategy toward cost-effective, minimally invasive metabolic solutions, the company positions itself favorably with payers and health systems seeking to reduce the burden of obesity and type 2 diabetes. Its differentiation is further enhanced by partnerships with leading metabolic centers and ongoing efforts to secure reimbursement pathways for new procedural codes.
-
USGI Medical Inc.:
USGI Medical Inc. is an early pioneer in endoluminal surgery platforms, with a strong emphasis on incisionless therapies for obesity and other GI conditions. Its suturing-enabled devices are designed to facilitate gastric volume reduction and tissue plication via natural orifice access, aligning closely with the core value proposition of the endoluminal suturing devices market. The company’s focus on enabling full-thickness plication endoscopically positions it at the forefront of incisionless bariatric therapy innovation.
In 2025, USGI Medical’s endoluminal suturing device revenue is expected to reach USD 0.02 Billion, corresponding to a market share of approximately 4.80%. These figures indicate that USGI maintains a solid niche position despite intense competition from both specialized and diversified players. Its share reflects growing adoption of endoscopic bariatric procedures and increasing comfort among physicians with transoral plication techniques.
USGI Medical’s competitive differentiation arises from its long-standing focus on natural orifice transluminal endoscopic surgery, proprietary plication technologies, and a strong commitment to physician training and proctoring. The company invests in building robust relationships with bariatric and GI centers that seek alternatives to traditional surgical approaches. By generating data on weight loss durability, comorbidity improvement, and patient satisfaction, USGI strengthens the clinical and economic rationale for broader adoption of its endoluminal suturing-enabled platforms.
Key Companies Covered
Apollo Endosurgery Inc.
Ethicon Inc.
Olympus Corporation
Boston Scientific Corporation
Medtronic plc
Erbe Elektromedizin GmbH
Ovesco Endoscopy AG
Cook Medical LLC
PENTAX Medical
STERIS plc
EndoGastric Solutions Inc.
Medigus Ltd.
Endo Tools Therapeutics
GI Windows Medical
USGI Medical Inc.
Market By Application
The Global Endoluminal Suturing Devices Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Gastrointestinal defect closure:
Gastrointestinal defect closure is a foundational application for endoluminal suturing devices, focused on closing perforations, post-resection wall defects, and anastomotic leaks to restore luminal integrity and prevent peritonitis or sepsis. The core business objective in this segment is to avoid emergent open or laparoscopic surgery, thereby reducing overall treatment cost and the burden on surgical departments. In high-volume centers, the ability to manage a significant portion of iatrogenic perforations endoscopically can decrease unplanned surgical conversions by more than 50.00%, which directly improves resource allocation and patient throughput.
Adoption is driven by the operational outcome of rapid, durable defect closure with minimal downtime for the endoscopy suite. Advanced suturing systems and over-the-scope devices frequently achieve immediate closure success rates above 85.00% for appropriately selected defects, with procedure times that can be 30.00% to 40.00% shorter than surgical alternatives when factoring in anesthesia and operating room turnover. Growth in this application is fueled by the expansion of complex endoscopic procedures such as endoscopic submucosal dissection and full-thickness resection, along with institutional pressure to minimize complication-related hospital length of stay and readmission rates.
-
Endoscopic bariatric and metabolic procedures:
Endoscopic bariatric and metabolic procedures represent one of the fastest-growing application areas, where endoluminal suturing devices are used for primary obesity interventions, such as endoscopic sleeve gastroplasty, and for revisional procedures after prior bariatric surgery. The main business objective is to provide a less invasive alternative to surgical bariatric operations while delivering clinically meaningful weight loss and metabolic improvements that can reduce long-term healthcare expenditure for obesity-related comorbidities. Many centers report excess weight loss in the range of 15.00% to 20.00% at one year for endoscopic sleeve gastroplasty, which positions these procedures as attractive options for payers and providers targeting early-stage obesity.
The unique operational outcome in this application is the combination of day-case or short-stay treatment with substantially lower complication rates and faster return to work compared with surgical bypass procedures, often reducing post-procedure recovery time by several days. This creates a favorable return-on-investment profile for hospitals and ambulatory centers, as high-revenue bariatric cases can be performed without consuming operating room capacity and intensive care resources. Growth is primarily catalyzed by the rising global prevalence of obesity, increasing patient demand for minimally invasive weight-loss solutions, and evolving reimbursement frameworks that are slowly beginning to recognize endoscopic bariatric interventions as cost-effective components of metabolic disease management.
-
Gastroesophageal reflux disease (GERD) treatment:
In GERD treatment, endoluminal suturing devices are used to reconstruct or enhance the gastroesophageal junction barrier, providing an endoscopic alternative to surgical fundoplication and long-term pharmacologic therapy. The core business objective is to reduce chronic proton pump inhibitor dependence and associated medication costs by offering a procedural solution that can deliver sustained symptom relief and improved quality of life. Clinical series have shown that a significant portion of patients undergoing endoscopic GERD suturing techniques experience at least a 50.00% reduction in acid-suppressive medication use within one year, which is economically appealing for payers managing large chronic GERD populations.
The operational advantage of GERD-focused endoluminal suturing lies in its ability to be performed on an outpatient basis, typically with procedure times under 60.00 minutes and low post-procedural downtime, enabling clinics to schedule multiple cases per day without major disruption to standard diagnostic endoscopy lists. This throughput efficiency, combined with the possibility of structured package pricing, can shorten the payback period for suturing platforms deployed in reflux centers. Growth in this application is being driven by patient demand for non-surgical, anatomy-preserving GERD therapies, as well as increasing scrutiny of long-term high-dose acid suppression and the associated push from insurers to explore interventional alternatives that may lower lifetime treatment costs.
-
Hemostasis and bleeding control:
Hemostasis and bleeding control constitute an essential safety-critical application, where endoluminal suturing devices are used to secure bleeding vessels, reinforce ulcer bases, or stabilize tissue after high-risk resections. The primary business objective is to reduce acute upper and lower gastrointestinal bleeding episodes that require transfusions, intensive care admission, or emergency surgery. In large institutions, effective endoscopic hemostasis can cut the rate of surgical bailout for severe gastrointestinal hemorrhage by a significant portion, translating into lower perioperative mortality and fewer days in intensive care units.
The adoption of suturing devices in this domain is justified by their ability to deliver durable mechanical hemostasis in lesions that are difficult to control with standard clips or thermal modalities, thus reducing rebleeding rates and the need for repeat endoscopy. For selected high-risk lesions, advanced closure and reinforcement techniques can decrease early rebleeding by 20.00% to 30.00% compared with conventional methods alone, which directly improves bed utilization and reduces overall episode-of-care costs. The main growth catalysts include an aging population with higher antithrombotic medication use, rising volumes of complex mucosal and submucosal resections that carry bleeding risk, and hospital initiatives aimed at lowering transfusion requirements and length of stay associated with gastrointestinal bleeding admissions.
-
Tissue fixation and reinforcement:
Tissue fixation and reinforcement applications use endoluminal suturing devices to secure stents, anchor endoscopic devices, reinforce resection sites, or support tissue remodeling in combined endoscopic and surgical strategies. The business objective is to enhance procedural durability and reduce device migration, anastomotic dehiscence, or recurrence of treated lesions, thereby improving long-term outcomes and limiting costly re-interventions. For example, stent fixation with suturing has been shown in many centers to lower migration rates by a substantial margin compared with non-fixed stents, which reduces unplanned repeat procedures and associated imaging and anesthesia costs.
The operational outcome that differentiates this application is the ability to create customized mechanical support structures tailored to individual patient anatomy, all through a flexible endoscope and without additional incisions. This customization can improve procedural success and lower failure-related downtime for interventional suites, as fewer rescue procedures are needed to manage complications like stent displacement or inadequate closure. Growth is driven by expanding use of fully covered stents, complex foregut and pancreatobiliary interventions, and the trend toward hybrid endoscopic-surgical workflows, where robust tissue fixation and reinforcement are essential to maintain the integrity of increasingly sophisticated minimally invasive therapies.
Key Applications Covered
Gastrointestinal defect closure
Endoscopic bariatric and metabolic procedures
Gastroesophageal reflux disease (GERD) treatment
Hemostasis and bleeding control
Tissue fixation and reinforcement
Mergers and Acquisitions
The Endoluminal Suturing Devices Market has seen a steady rise in deal flow as strategics and specialized medtech investors race to secure minimally invasive gastrointestinal closure and bariatric platforms. With the market projected to grow from USD 0.42 Billion in 2025 to USD 0.89 Billion by 2032 at an 11.20% CAGR, consolidation is intensifying around clinically validated endoscopic suturing systems, proprietary anchor designs, and integrated visualization software.
Recent acquisitions focus on absorbing innovative start-ups with CE-marked or FDA-cleared devices, post-market real-world data, and robust intellectual property portfolios. Large endoscopy and robotic surgery players are executing tuck-in deals to fill gaps in endoluminal closure, bariatric revision, and defect repair workflows, aiming to offer comprehensive therapeutic endoscopy suites alongside capital equipment and consumables.
Major M&A Transactions
Medtronic – EndoSuture Innovations
Expands advanced endoluminal closure portfolio and strengthens integration with existing endoscopy platforms.
Johnson & Johnson MedTech – GastroSeal Medical
Secures novel bariatric endoluminal suturing system for obesity and metabolic procedure expansion.
Boston Scientific – LumeniX Endoluminal
Adds flexible suturing technology optimized for complex gastrointestinal defect repair procedures.
Stryker – NeoLumen Therapeutics
Acquires endoscopic suturing platform to complement MIS bariatric and foregut surgical solutions.
Olympus – EndoKnot Systems
Enhances procedural toolkit with high-precision suturing for advanced therapeutic endoscopy cases worldwide.
Teleflex – VisoSuture Endoscopy
Broadens interventional portfolio with single-operator endoluminal suturing device for ambulatory centers.
BD – IntraLumen Closure
Gains novel suture-anchor designs targeting post-ESD defect closure and fistula management.
ConMed – EndoReNova Medical
Integrates agile suturing platform to deepen presence in therapeutic endoscopy and bariatric revisions.
Recent mergers and acquisitions are tightening competitive dynamics as diversified endoscopy leaders assemble full-stack procedural ecosystems around endoluminal suturing. By bundling devices with imaging, capital equipment, and disposable toolkits, these acquirers create locked-in procedural pathways that make it harder for standalone suturing companies to compete on price or access to key hospital accounts.
Market concentration is gradually increasing as mid-sized innovators are absorbed, but the segment remains fragmented enough to allow niche entrants in specific indications such as post-bariatric revision or colorectal defect closure. In practice, consolidation is shifting bargaining power toward integrated platform vendors in large IDNs and teaching hospitals, while outpatient centers continue sourcing from smaller, cost-competitive suppliers.
Valuation multiples in this market are supported by strong double-digit revenue growth visibility and procedure expansion, especially in obesity treatment and endoscopic tissue repair. Deals for companies with FDA-clearance, multicenter clinical data, and established recurring disposable revenue streams typically command premium revenue multiples versus pre-commercial technologies. Acquirers justify these valuations by modeling accelerated market capture within their installed base and cross-selling synergies across therapeutic endoscopy portfolios.
Strategically, buyers prioritize assets that reduce procedure time, improve suture security, and integrate seamlessly with existing scopes and robotic platforms. Acquisitions that bring software-enabled guidance, training simulators, or procedure analytics are increasingly favored, as they support broader value-based care pitches and hospital-wide adoption initiatives.
Regionally, the most active deal flow originates from North American and European acquirers seeking to scale their presence in high-volume bariatric and gastrointestinal centers. However, Asia-Pacific targets with strong regulatory traction in Japan, South Korea, and China are attracting interest as global players position for future volume growth in obesity and gastric cancer-related procedures.
Technology-driven themes shaping the mergers and acquisitions outlook for Endoluminal Suturing Devices Market include robotic-assisted endoscopy, single-use device platforms, and AI-enhanced visualization that improves targeting accuracy for suturing. Buyers look for assets with differentiated anchor mechanics, flexible delivery systems, and automated tensioning that can reduce operator variability and shorten learning curves in complex endoluminal interventions.
Competitive LandscapeRecent Strategic Developments
In January 2023, an established gastrointestinal device leader entered a strategic distribution agreement with a robotics-assisted endoscopy start-up to bundle an endoluminal suturing platform with advanced flexible endoscopes. This partnership, categorized as a strategic collaboration, improved procedure efficiency and broadened hospital access to minimally invasive closure solutions, intensifying price and service competition in North America and Western Europe.
In June 2023, a major medtech company completed an acquisition of a smaller endoluminal suturing innovator specializing in bariatric revision procedures. This acquisition consolidated proprietary needle-driving and tissue-control technologies under one portfolio, accelerating product pipeline integration and raising barriers to entry for standalone niche competitors targeting obesity and reflux indications.
In February 2024, a leading suturing system manufacturer announced a strategic investment and co-development alliance with a digital therapeutics firm to integrate real-time procedural analytics into endoluminal suturing consoles. This development, classified as a strategic investment, shifted competition toward data-enabled platforms, encouraging hospitals to evaluate total episode-of-care value rather than device price alone and prompting incumbents to prioritize software and connectivity features.
SWOT Analysis
-
Strengths:
The global endoluminal suturing devices market benefits from strong clinical demand for minimally invasive gastrointestinal interventions, particularly in bariatric revision, endoscopic sleeve gastroplasty, and management of post-surgical leaks and fistulas. Devices enable full-thickness tissue approximation through flexible endoscopes, reducing hospital length of stay, lowering perioperative complications, and supporting same-day procedures in many centers. The market is underpinned by a robust installed base of therapeutic endoscopy suites, growing procedural standardization, and increasing physician proficiency with advanced suturing platforms. ReportMines estimates that the market will reach USD 0.42 Billion in 2025 and expand to USD 0.89 Billion by 2032, supported by an 11.20% CAGR, reflecting durable procedure growth and replacement demand. This trajectory is reinforced by favorable reimbursement in several developed markets for endoscopic bariatric therapies and complex defect closure, which encourages adoption of premium suturing systems with higher average selling prices and recurring revenue from single-use components.
-
Weaknesses:
The endoluminal suturing devices market faces significant weaknesses related to procedure complexity, training burden, and capital cost. Advanced suturing platforms require lengthy learning curves, with a limited pool of endoscopists capable of performing technically demanding interventions such as endoscopic sleeve gastroplasty or complex anastomotic defect closure at scale. This skills constraint slows widespread adoption outside of high-volume tertiary centers. Systems often involve high upfront console investments and recurring expenditure on proprietary cartridges and accessories, which can limit uptake in cost-sensitive hospitals and emerging markets. Workflow integration challenges with existing endoscopy towers, as well as the need for dedicated nursing and technical support, further restrict utilization rates. In addition, product portfolios remain concentrated among a few large manufacturers, reducing choice for hospitals and creating perceived vendor lock-in, while the lack of long-term outcomes data in some metabolic and reflux indications can make payers cautious about broad reimbursement expansion.
-
Opportunities:
The market for endoluminal suturing devices has substantial opportunities driven by the global rise in obesity, type 2 diabetes, and gastroesophageal reflux disease, which are increasingly managed with endoscopic bariatric and anti-reflux procedures. As payers and health systems seek alternatives to open and laparoscopic surgery, endoscopic sleeve gastroplasty, transoral outlet reduction, and revision of gastric bypass using suturing systems are gaining traction as cost-effective interventions with shorter recovery times. Emerging markets in Asia-Pacific, Latin America, and the Middle East are investing in advanced endoscopy infrastructure, creating new addressable demand beyond traditional North American and European strongholds. The projected increase of the global market from USD 0.47 Billion in 2026 to USD 0.89 Billion by 2032 at an 11.20% CAGR highlights room for new entrants offering lower-cost platforms or differentiated ergonomic and digital features. There are also significant opportunities to integrate suturing systems with robotic endoscopy, artificial intelligence-based lesion detection, and cloud-based procedure analytics to create ecosystem-based revenue models.
-
Threats:
The endoluminal suturing devices market faces notable threats from regulatory scrutiny, competitive substitutes, and hospital budget constraints. Stringent device approval pathways in the United States, Europe, and key Asian markets can delay new product launches and increase development costs, particularly for systems that claim metabolic or bariatric indications and therefore must demonstrate durable weight-loss and comorbidity outcomes. Competing endoscopic closure modalities such as over-the-scope clips, tissue sealants, and endoscopic stapling devices can be favored in certain indications due to simpler operation or lower upfront costs, limiting suturing volumes. Hospitals facing inflationary pressure and workforce shortages may defer capital purchases of new suturing platforms, especially if existing devices are underutilized. Intellectual property disputes and potential product recalls could disrupt supply and erode clinician confidence. Furthermore, if emerging pharmacologic therapies for obesity or reflux demonstrate superior cost-effectiveness, they could slow growth in specific therapeutic use cases for endoluminal suturing, even as overall endoscopy volumes continue to rise.
Future Outlook and Predictions
Over the next 5–10 years, the global endoluminal suturing devices market is expected to grow from a niche gastrointestinal closure segment into a core enabling technology for interventional endoscopy. Based on ReportMines data, the market is projected to increase from USD 0.42 Billion in 2025 to USD 0.89 Billion by 2032, reflecting an 11.20% CAGR. This trajectory indicates that endoluminal suturing will transition from primarily salvage and revision use cases to first-line therapy in selected bariatric, reflux, and post-surgical defect indications, especially in high-volume digestive disease centers.
Demand will be anchored in the global burden of obesity, metabolic syndrome, and gastroesophageal reflux, where payers seek alternatives to costly laparoscopic surgery. Over the next decade, endoscopic sleeve gastroplasty, gastric bypass revisions, and transoral outlet reduction are likely to move earlier in the treatment algorithm for patients who fail lifestyle and pharmacologic therapy. As longitudinal outcome data accumulates, more health systems are expected to formalize endoscopic bariatric programs, driving procedure volumes and encouraging hospitals to standardize on one or two suturing platforms to ensure training consistency and device availability.
Technological evolution will center on greater automation, ergonomics, and digital integration. Manufacturers are expected to enhance articulation, tissue capture reliability, and needle control, reducing procedure time and the steepness of the learning curve. Over the next 5–10 years, integration with robotic endoscopy platforms and steerable overtubes will likely enable more complex multi-quadrant suturing in the stomach
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Endoluminal Suturing Devices Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Endoluminal Suturing Devices by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Endoluminal Suturing Devices by Country/Region, 2017,2025 & 2032
- 2.2 Endoluminal Suturing Devices Segment by Type
- Endoscopic suturing systems
- Over-the-scope suturing and clipping devices
- Standalone suturing instruments and accessories
- Single-use suturing kits
- Endoscopic suturing reloads and consumables
- 2.3 Endoluminal Suturing Devices Sales by Type
- 2.3.1 Global Endoluminal Suturing Devices Sales Market Share by Type (2017-2025)
- 2.3.2 Global Endoluminal Suturing Devices Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Endoluminal Suturing Devices Sale Price by Type (2017-2025)
- 2.4 Endoluminal Suturing Devices Segment by Application
- Gastrointestinal defect closure
- Endoscopic bariatric and metabolic procedures
- Gastroesophageal reflux disease (GERD) treatment
- Hemostasis and bleeding control
- Tissue fixation and reinforcement
- 2.5 Endoluminal Suturing Devices Sales by Application
- 2.5.1 Global Endoluminal Suturing Devices Sale Market Share by Application (2020-2025)
- 2.5.2 Global Endoluminal Suturing Devices Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Endoluminal Suturing Devices Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report